Patients
NSCLC
MAY, NEUROENDOCRINE CARCINOMA, NSCLC
A total of 41 patients with EGFR‐mutated NSCLC were enrolled between May 2019 and April 2021 from 14 institutions. The data cut‐off date was April 30, 2022. The baseline patient characteristics are summarized in Table Baseline patient characteristics (Abbreviations: EGFR, epidermal growth factor receptor; LCNEC, large‐cell neuroendocrine carcinoma; TKIs, tyrosine kinase inhibitors.Body surface area was calculated using the Du Bois formula.One patient each had L861Q, exon20 insertion, and G719X compounded with S768I.